Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer

International Journal of Clinical Oncology

Volumn 20, Issue 2, 2015, Pages 207-239

  Watanabe, Toshiaki ^a   Itabashi, Michio ^b   Shimada, Yasuhiro ^c   Tanaka, Shinji ^d   Ito, Yoshinori ^c   Ajioka, Yoichi ^e   Hamaguchi, Tetsuya ^c   Hyodo, Ichinosuke ^f   Igarashi, Masahiro ^g   Ishida, Hideyuki ^h   Ishihara, Soichiro ^a   Ishiguro, Megumi ⁱ   Kanemitsu, Yukihide ^c   Kokudo, Norihiro ^a   Muro, Kei ^j   Ochiai, Atsushi ^c   Oguchi, Masahiko ^g   Ohkura, Yasuo ^k   Saito, Yutaka ^c   Sakai, Yoshiharu ^l   Ueno, Hideki ^m   Yoshino, Takayuki ⁿ   Boku, Narikazu ^o   Fujimori, Takahiro ^p   Koinuma, Nobuo ^q   Morita, Takayuki ^r   Nishimura, Genichi ^s   Sakata, Yuh ^t   Takahashi, Keiichi ^u   Tsuruta, Osamu ^v   Yamaguchi, Toshiharu ^g   Yoshida, Masahiro ^w   Yamaguchi, Naohiko ^x   Kotake, Kenjiro ^y   Sugihara, Kenichi ⁱ   more..

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^e NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^f UNIVERSITY OF TSUKUBA   (Japan)

^g CANCER CHEMOTHERAPY CENTER   (Japan)

^h SAITAMA MEDICAL UNIVERSITY   (Japan)

ⁱ TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^j AICHI CANCER CENTER HOSPITAL   (Japan)

^k KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l KYOTO UNIVERSITY   (Japan)

^m NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

ⁿ NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^o ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^p DOKKYO MEDICAL UNIVERSITY   (Japan)

^q TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^r AOMORI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^s Japanese Red Cross Kanazawa Hospital   (Japan)

^t Misawa City Hospital   (Japan)

^u TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^v KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^w INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^x TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

^y TOCHIGI CANCER CENTER   (Japan)

more..

Author keywords

Chemotherapy; Colorectal cancer; Endoscopy; Guideline; Radiotherapy; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADJUVANT RADIOTHERAPY; BRAIN NEOPLASMS; CANCER STAGING; COLONIC NEOPLASMS; DISSECTION; FEMALE; GASTROINTESTINAL ENDOSCOPY; HUMAN; INTESTINE MUCOSA; JAPAN; LIVER NEOPLASMS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; PALLIATIVE THERAPY; PATHOLOGY; PRACTICE GUIDELINE; RECTAL NEOPLASMS; SECONDARY; SURGERY; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DISSECTION; ENDOSCOPY, GASTROINTESTINAL; FEMALE; HUMANS; INTESTINAL MUCOSA; JAPAN; LIVER NEOPLASMS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PALLIATIVE CARE; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS;

EID: 84939959446     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-015-0801-z     Document Type: Article

References (134)

1. Japanese Society for Cancer of the Colon and Rectum (2014) JSCCR Guidelines 2014 for the Treatment of Colorectal Cancer. Kanehara and Co. Ltd, Tokyo
2. Fukui T, Yamaguchi N, Morizane T et al (2014) Minds handbook for clinical practice guideline development 2014. Igaku Shoin, Tokyo
3. Aihara M, Mihara H, Murayama T et al (2010) GRADE System for clinical practice guideline—therapeutic intervention. Toppan Media, Hirosaki
4. Atkins D, Best D, Briss PA et al (2004) The GRADE* Working Group: Grading quality of evidence and strength of recommendations. BMJ 328:1490–1494 printed, abridged version
5. Guyatt GH, Oxman AD, Vist G et al (2008) GRADE Working Group: Rating quality of evidence and strength of recommendations. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924–926
6. Guyatt GH, Oxman AD, Kunz R et al (2008) GRADE Working Group: Rating quality of evidence and strength of recommendations: what is “quality of evidence” and why is it important to clinicians? BMJ 336:995–998
7. Schunemann HJ, Oxman AD, Brozek J et al (2008) GRADE Working Group: Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 336:1106–1110
8. Guyatt GH, Oxman AD, Kunz R et al (2008) GRADE Working Group: Rating quality of evidence and strength of recommendations: Incorporating considerations of resources use into grading recommendations. BMJ 336:1170–1173
9. Guyatt GH, Oxman AD, Kunz R et al (2008) GRADE Working Group: Rating quality of evidence and strength of recommendations: going from evidence to recommendations. BMJ 336:1049–1051
10. Jaeschke R, Guyatt GH, Dellinger P et al (2008) GRADE Working Group. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ 337:a744
11. Guyatt G, Oxman AD, Akl EA et al (2011) GRADE guidelines: 1. Introduction–GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64:383–394
12. Guyatt GH, Oxman AD, Kunz R et al (2011) GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol 64:395–400
13. Balshem H, Helfand M, Schunemann HJ et al (2011) GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64:401–406
14. Guyatt GH, Oxman AD, Vist G et al (2011) GRADE guidelines: 4. Rating the quality of evidence––study limitations (risk of bias). J Clin Epidemiol 64:407–415
15. Guyatt GH, Oxman AD, Montori V et al (2011) GRADE guidelines: 5. Rating the quality of evidence––publication bias. J Clin Epidemiol 64:1277–1282
16. Guyatt GH, Oxman AD, Kunz R et al (2011) GRADE guidelines: 6. Rating the quality of evidence imprecision. J Clin Epidemiol 64:1283–1293
17. Guyatt GH, Oxman AD, Kunz R et al (2011) GRADE Working Group: GRADE guidelines: 7. Rating the quality of evidence––inconsistency. J Clin Epidemiol 64:1294–1302
18. Guyatt GH, Oxman AD, Kunz R et al (2011) GRADE Working Group. GRADE guidelines: 8. Rating the quality of evidence––indirectness. J Clin Epidemiol 64:1303–1310
19. Guyatt GH, Oxman AD, Sultan S et al (2011) GRADE Working Group. GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol 64:1311–1316
20. Brunetti M, Shemilt I, Pregno S et al (2013) GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence. J Clin Epidemiol 66:140–150
21. Guyatt G, Oxman AD, Sultan S et al (2013) GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. J Clin Epidemiol 66:151–157
22. Guyatt G, Oxman AD, Santesso N et al (2013) GRADE guidelines: 12. Preparing summary of findings tables–binary outcomes. J Clin Epidemiol 66:158–172
23. Thorlund K, Oxman AD, Walter SD et al (2013) GRADE guidelines: 13. Preparing summary of findings tables-continuous outcomes. J Clin Epidemiol 66:173–183
24. Andrews J, Guyatt G, Oxman AD et al (2013) GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations J. Clin Epidemiol 66:719–725
25. Andrews JC, Schunemann HJ, Oxman AD et al (2013) GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation’s direction and strength. J Clin Epidemiol 66:726–735
26. Japanese Society for Cancer of the Colon and Rectum (2013) Japanese classification of colorectal carcinoma. The 8th Edition. Kanehara & CO., LTD. Tokyo
27. Tanaka S, Oka S, Chayama K (2008) Colorectal endoscopic submucosal dissection (ESD): the present status and future perspective including its differentiation from endoscopic mucosal resection (EMR). J Gastroenterol 43:641–651
28. Kudo S (1993) Endoscopic mucosal resection of flat and depressed early colorectal cancer. Endoscopy 25:455–461
29. Japanese Society for Cancer of the Colon and Rectum: Multi-institutional registry of large bowel cancer in Japan, Cases treated in 2000–2002, vol. 29 (2011), Cases treated in 2003–2004, vol. 30 (2012)
30. Heald RJ, Husband EM, Ryall RD (1982) The mesorectum in rectal cancer surgery—the clue to pelvic recurrence? Br J Surg 69:613–616
31. MacFarlane JK, Ryall RD, Heald RJ (1993) Mesorectal excision for rectal cancer. Lancet 341:457–460
32. Enker WE, Thaler HT, Cranor ML et al (1995) Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg 181:335–346
33. Lowry AC, Simmang CL, Boulos P et al (2001) Consensus statement of definitions for anorectal physiology and rectal cancer. Dis Colon Rectum 44:915–919
34. Sugihara K, Kobayashi H, Kato T et al (2006) Indication and benefit of pelvic sidewall dissection for rectal cancer. Dis Colon Rectum 49:1663–1672
35. Murata S, Moriya Y, Akasu T et al (1998) Resection of both hepatic and pulmonary metastases in patients with colorectal carcinoma. Cancer 83:1086–1093
36. Kobayashi K, Kawamura M, Ishihara T (1999) Surgical treatment for both pulmonary and hepatic metastases from colorectal cancer. J Thorac Cardiovasc Surg 118:1090–1096
37. Portier G, Elias D, Bouche O et al (2006) Multicentric randomized trial of adjuvant fluorouracil and folnic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 24:4976–4982
38. Mitry E, Fields AL, Bleiberg H et al (2008) Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 26:4906–4911
39. Robinson BJ, Rice TW, Strong SA et al (1999) Is resection of pulmonary and hepatic metastases warranted in patients with colorectal cancer? J Thorac Cardiovasc Surg 117:66–76
40. Lambert LA, Colacchio TA, Barth RJ Jr (2000) Interval hepatic resection of colorectal metastases improves patient selection. Arch Surg 135:473–479
41. Adam R (2007) Developing strategies for liver metastases from colorectal cancer. Semin Oncol 34(2 Suppl 1):S7–S11
42. Lam VW, Spiro C, Laurence JM et al (2012) A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. Ann Surg Oncol 19:1292–1301
43. Regnard JF, Grunenwald D, Spaggiari L et al (1998) Surgical treatment for hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg 66:214–218
44. Beppu T, Matsuda T, Maeda K et al (2000) Microwave coagulation therapy for metastatic liver tumor. Surg Therapy 83:237–242
45. Shibata T, Niinobu T, Ogata N et al (2000) Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma. Cancer 89:276–284
46. Park IJ, Kim HC, Yu CS et al (2008) Radiofrequency ablation for metachronous liver metastasis from colorectal cancer after curative surgery. Ann Surg Oncol 15:227–232
47. Wong SL, Mangu PB, Choti MA et al (2010) American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 28:493–508
48. Tree AC, Khoo VS, Eeles RA et al (2013) Stereotactic body radiotherapy for oligometastases. Lancet Oncol 14:e28–e37
49. Patchell RA, Tibbs PA, Walsh JW et al (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494–500
50. National Institute of Health Consensus Conference (1990) Adjuvant therapy for patients with colon and rectal cancer. JAMA 264:1444–1450
51. Benson AB 3rd, Schrag D, Somerfield MR et al (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22:3408
52. Schmoll HJ, Van Cutsem E, Stein A et al (2012) ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 23:2479–2516
53. Haller DG, Catalano PJ, Macdonald JS et al (2005) Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 23:8671–8678
54. Scheithauer W, Rosen H, Kornek GV et al (1993) Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 306:752–755
55. Simmonds PC (2000) Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. Br Med J 321:531–535
56. Cunningham D, Pyrhonen S, James RD et al (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413–1418
57. de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947
58. Goldberg R, Sargent D, Morton R et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30
59. Saltz LB, Clarke S, Díaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26:2013–2019
60. Cassidy J, Clarke S, Díaz-Rubio E et al (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006–2012
61. Tournigand C, André T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–237
62. Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041–1047
63. Fuchs CS, Marshall J, Mitchell E et al (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC–C Study. J Clin Oncol 25:4779–4786
64. Fuchs CS, Marshall J, Barrueco J et al (2008) Randomized, controlled trial of irinotecan plus infusional, bolus or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC–C study. J Clin Oncol 26:689–690
65. Bokemeyer C, Bondarenko I, Makhson A et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663–671
66. Douillard JY, Siena S, Cassidy J et al (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin(FOLFOX4)versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28:4697–4705
67. Van Cutsem E, Köhne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417
68. Köhne CH, Hofheinz R, Mineur L et al (2012) First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol 138:65–72
69. Falcone A, Ricci S, Brunetti I et al (2007) Gruppo Oncologico Nord Ovest: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan(FOLFOXIRI)compared with infusional fluorouracil, leucovorin, and irinotecan(FOLFIRI)as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670–1676
70. Petrelli N, Herrera L, Rustum Y et al (1987) A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5:1559–1565
71. de Gramont A, Bosset JF, Milan C et al (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15:808–815
72. Hurwitz H, Fehrenbacher L, Hainsworth JD et al (2005) Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23:3502–3508
73. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al (2003) Phase II, randomized trial comparing Bevacizumab plus fluorouracil(FU)/leucovorin(LV)with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60–65
74. Hoff PM, Ansari R, Batist G et al (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19:2282–2292
75. Van Cutsem E, Twelves C, Cassidy J et al (2001) Xeloda Colorectal Cancer Study Group: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19:4097–4106
76. Tebbutt NC, Wilson K, Gebski VJ et al (2010) Capecitabine, bevacizumab, and mitomycin in first–line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 28:3191–3198
77. Shirao K, Hoff PM, Ohtsu A et al (2004) Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur(UFT)plus oral leucovorin(LV)regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. J Clin Oncol 22:3466–3474
78. Douillard JY, Hoff PM, Skillings JR et al (2002) Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20:3605–3616
79. Carmichael J, Popiela T, Radstone D et al (2002) Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20:3617–3627
80. Bennouna J, Sastre J, Arnold D et al (2013) ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomized phase 3 trial. Lancet Oncol 14:29–37
81. Muro K, Boku N, Shimada Y et al (2010) Irinotecan plus S-1 (IRIS)versus fluorouracil and folinic acid plus irinotecan (FOLFIRI)as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 11:853–860
82. Sobrero AF, Maurel J, Fehrenbacher L et al (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311–2319
83. Peeters M, Price TJ, Hotko YS, et al (2010) Randomized phase III study of panitumumab (pmab) with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Patient-reported outcomes (PRO). 2010 ASCO Gastrointestinal Cancers Symposium. (Abstr 282)
84. Rothenberg ML, Oza AM, Bigelow RH et al (2003) Superiority of oxaliplatin and fluorouracil–leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil–leucovorin: interim results of a phase III trial. J Clin Oncol 21:2059–2069
85. Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539–1544
86. Rothenberg ML, Cox JV, Butts C et al (2008) Capecitabine plus oxaliplatin (XELOX)versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4)as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 19:1720–1726
87. Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345
88. Jonker DJ, O’Callaghan CJ, Karapetis CS et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040–2048
89. Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765
90. Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy–refractory metastatic colorectal cancer. J Clin Oncol 25:1658–1664
91. Amado RG, Wolf M, Peeters M et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634
92. Grothey A, Van Cutsem E, Sobrero A et al (2013) CORRECT Study Group: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303–312
93. Meta-Analysis Group in Cancer (1996) Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 88:252–258
94. Skibber JM, Hoff PM, Minsky BD et al (2001) Cancer of the rectum. In: Devita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 6th edn. Lippincott, Williams and Wilkins, Philadelphia, pp 1271–1318
95. Swedish Rectal Cancer Trial (1997) Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 336:980–987
96. Camma C, Giunta M, Fiorica F et al (2000) Preoperative radiotherapy for resectable rectal cancer. A meta-analysis. J Am Med Assoc 284:1008–1015
97. Colorectal Cancer Collaborative Group (2001) Adjuvant radiotherapy for rectal cancer: a systematic overview of 22 randomised trials involving 8507 patients. Lancet 358:1291–1304
98. Kapiteijn E, Marijnen CA, Nagtegaal ID et al (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638–646
99. Peeters KC, Marijnen CA, Nagtegaal ID et al (2007) The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 246:693–701
100. van Gijn W, Marijnen CA, Nagtegaal ID et al (2011) Dutch Colorectal Cancer Group: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 12:575–582
101. Marijnen CA, van de Velde CJ, Putter H et al (2005) Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 23:1847–1858
102. Peeters KC, van de Velde CJ, Leer JW et al (2005) Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients: a Dutch colorectal cancer group study. J Clin Oncol 23:6199–6206
103. Francois Y, Nemoz CJ, Baulieux J et al (1999) Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: The Lyon R90-01 randomized trial. J Clin Oncol 17:2396–2402
104. Bosset JF, Collette L, Calais G et al: EORTC Radiotherapy Group Trial 22921 (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114–1123
105. Gerard JP, Conroy T, Bonnetain F et al (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 24:4620–4625
106. Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al (2006) Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 93:1215–1223
107. Ngan SY, Burmeister B, Fisher RJ et al. (2012) Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 30:3827–3833
108. Sauer R, Becker H, Hohenberger W, et al; German Rectal Cancer Study Group (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351: 1731–1740
109. Hofheinz RD, Wenz F, Post S et al (2012) Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 13:579–588
110. Roh MS, Yothers GA, O’Connell MJ et al (2011) The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R–04. J Clin Oncol (Meeting Abstracts) 29:3503
111. Aschele C, Cionini L, Lonardi S et al (2011) Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR–01 randomized phase III trial. J Clin Oncol 29:2773–2780
112. Gérard JP, Azria D, Gourgou-Bourgade S et al (2010) Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405–Prodige 2. J Clin Oncol 28:1638–1644
113. Gérard JP, Azria D, Gourgou-Bourgade S et al (2012) Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 30:4558–4565
114. Rödel C, Liersch T, Becker H et al (2012) German Rectal Cancer Study Group: Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO–04 randomised phase 3 trial. Lancet Oncol 13:679–687
115. Cancer pain relief and palliative care (1990) Report of a WHO expert committee. WHO Technical Report Series 804. WHO, Geneva, 21–22
116. Renehan AG, Egger M, Saunders MP et al (2002) Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trial. Br Med J 324:813–816
117. Figueredo A, Rumble RB, Maroun J et al (2003) Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer 6:26
118. Renehan AG, Egger M, Saunders MP et al (2005) Mechanisms of improved survival from intensive followup in colorectal cancer: a hypothesis. Br J Cancer 92:430–433
119. Jeffery M, Hickey BE, Hider PN (2007) Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 24: CD002200
120. Tjandra JJ, Chan MK (2007) Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum 50:1783–1799
121. Bruinvels D, Stiggelbout A, Kievit J et al (1994) Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg 219:174–182
122. Fleischer D, Goldberg S, Browning T et al (1989) Detection and surveillance of colorectal cancer. JAMA 261:580–585
123. Green RJ, Metlay JP, Propert K et al (2002) Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. Ann Int Med 136:261–269
124. Berman J, Cheung R, Weiberg D (2000) Surveillance after colorectal cancer resection. Lancet 355:395–399
125. Japanese Society for Cancer of the Colon and Rectum (2012) JSCCR Guidelines 2012 for the Clinical Practice of Hereditary Colorectal Cancer. Kanehara & CO., LTD. Tokyo
126. Ueno H, Mochizuki H, Hashiguchi Y et al (2004) Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 127:385–394
127. Kitajima K, Fujimori T, Fujii S et al (2004) Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study. J Gastroenterol 39:534–543
128. Tanaka S, Haruma K, Oh-e H et al (2000) Conditions of curability after endoscopic resection for colorectal carcinoma with submucosally massive invasion. Oncol Rep 7:783–788
129. Japanese Society for Cancer of the Colon and Rectum (1980) General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus. The 2nd Edition. Kanehara & CO., LTD. Tokyo
130. Japanese Society for Cancer of the Colon and Rectum (1994) General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus. The 5th Edition. Kanehara & CO., LTD. Tokyo
131. Japanese Society for Cancer of the Colon and Rectum (2005) JSCCR Guidelines 2005 for the Treatment of Colorectal Cancer. Kanehara & CO., LTD. Tokyo
132. Oka S, Tanaka S, Kanao H et al (2011) Mid-term prognosis after endoscopic resection for submucosal colorectal carcinoma: summary of a multicenter questionnaire survey conducted by the colorectal endoscopic resection standardization implementation working group in Japanese Society for Cancer of the Colon and Rectum. Dig Endosc 23:190–194
133. Matsuda T, Fukuzawa M, Uraoka T et al (2011) Risk of lymph node metastasis in patients with pedunculated type early invasive colorectal cancer: a retrospective multicenter study. Cancer Sci 102:1693–1697
134. Ikematsu H, Yoda Y, Matsuda T et al (2013) Long-term outcomes after resection for submucosal invasive colorectal cancers. Gastroenterology 144:551–559